FDA Moves Forward on Aducanumab
By
Phil Gutis
| August 7th, 2020
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
Can Memory Loss Be Reversed? An Experimental Drug Reports Success, Pursues Clinical Trials
By
Alexandra Marvar
| August 7th, 2020
In a new mouse study, Salk researchers found a drug, CMS121, that appears to treat neurodegeneration in mice. Researchers at the Salk Institute for…
12 Things You Can Do To Help Prevent or Delay Dementia
By Nicholas Chan | August 6th, 2020
While dementia is not necessarily preventable, scientists now understand even more clearly the extent to which some lifestyle changes can significantly lower one’s odds…
9/11 First Responders Showing Signs of Cognitive Impairment and Dementia
By
Alexandra Marvar
| August 5th, 2020
Nearly 20 years after the 9/11 terrorist attacks, clinicians are seeing more 9/11 first responders display signs of cognitive disorders and possible dementia. Two…
The Physical Toll of COVID-19 Is Compounded By Its Psychological Impacts
By Nicholas Chan | August 3rd, 2020
The public health repercussions of contracting COVID-19 have been front-and-center for months. Beyond the disease’s physical effects, researchers say that its psychological toll may…
Biden, Trump, and Cognitive Decline: An Expert’s Primer on the Cognitive Tests That Have Become a 2020 Campaign Issue
By
Christy Turner
| August 3rd, 2020
Alzheimer’s and memory care expert Christy Turner explains cognitive screening: why it’s important, how it works, and how the current media frenzy around Joe…
A Safer Dementia-Related Psychosis Treatment Grows Closer to FDA Approval
By Alexandra Marvar | July 31st, 2020
Phase III trials for experimental dementia-related psychosis treatment pimavanserin draw interest at AAIC; FDA begins consideration of the drug approval. As many as half…
Follow us